Tempest Therapeutics entered into an exclusive collaboration, option, and license agreement with Heibei Senlang Biotechnology Co., Ltd. on September 14, 2026. The deal grants Tempest a four-month exclusive option to acquire worldwide rights (excluding Greater China) to develop and commercialize Senlang’s in vivo CAR-T technology. Exercising the option requires an approximate $447,000 fee. A definitive license would impose escalating annual maintenance fees from $10 million to $14 million over three years, a 6% royalty on net sales, and sublicense revenue sharing. Tempest must use commercially reasonable efforts to develop at least one product and meet specific IND-filing or business-development milestones. The company operates in the biotechnology industry, developing in vivo CAR-T therapies for cancer and autoimmune diseases.

Tempest Therapeutics entered into a securities purchase agreement on September 11, 2026, closing on September 15, to raise approximately $2.5 million in gross proceeds through a private placement of pre-funded warrants and accompanying Series C and D warrants. The company issued 3,105,591 pre-funded warrants at a combined price of $0.804 per unit with the common warrants exercisable at $0.805 per share. Proceeds are designated for working capital and general corporate purposes. This transaction represents significant new financing for the biotechnology company.

Tempest Therapeutics announced that Justin Trojanowski resigned as Principal Financial Officer and Principal Accounting Officer effective September 1, 2026. The Board appointed Nicholas Rossettos as Chief Financial Officer, Treasurer, and Corporate Secretary on the same date. Rossettos brings over 30 years of experience in biopharmaceutical finance, including prior roles at TransCode Therapeutics and Sernova Corp. This executive transition is material to investors as it involves key financial leadership changes. The company operates in the biotechnology industry.

Tempest Therapeutics adjourned its reconvened special meeting on August 17, 2026, because the proposal to replace supermajority voting requirements and permit stockholder action by written consent failed to receive the required 75% affirmative vote. The company will reconvene the meeting on September 15, 2026, to seek approval for the same amendment. Tempest Therapeutics operates in the biotechnology industry.

Tempest Therapeutics reported second quarter 2026 financial results, posting a net loss of $5.2 million ($0.34 per share) compared to $7.9 million in the prior year period. Cash and cash equivalents decreased to $0.8 million from $7.7 million at year-end 2025, primarily due to one-time transaction costs associated with an February 2026 asset acquisition, offset by net proceeds of $1.7 million from a March private placement and $1.7 million from a warrant inducement in the second quarter. The company executed a development collaboration with Senlang Biotechnology for its CD7-targeted TPST-4003 candidate, with first patient dosing expected in Q4 2026. Additionally, Tempest appointed Drake Richey and John Yee to its Board of Directors and Andrew Fang as Head of Business Development. The company operates in the biotechnology industry, developing next-generation in vivo CAR-T therapies for oncology and autoimmune indications.